Cardio Diagnostics Holdings Inc. Common stock
CDIO XNASAbout Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| TTM 2025 | $14.8K | $-6,498,167 | $-3.71 |
| FY 2025 | $14.8K | $-6,498,167 | $-3.71 |
| Q3 2025 | $2.9K | $-1,714,536 | $-0.98 |
| Q2 2025 | $7.5K | $-1,683,199 | $-0.97 |
Earnings & Analyst Ratings
TickerDaily Coverage
Get CDIO Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Cardio Diagnostics Holdings Inc. Common stock.